(JTA) — As the American drug company Moderna announced Monday that it had developed a COVID-19 vaccine that is 94.5% effective, Israeli scientist Tal Zaks was among the company leaders touting the good news to the media.
That’s because Zaks, who earned a doctorate at Ben-Gurion University in Beersheba, is the chief medical officer at Moderna and has been involved in overseeing its unprecedentedly rapid push for a coronavirus vaccine.
“The overall effectiveness has been remarkable … it’s a great day,” he told BBC News.
In an interview last month with The Jerusalem Post, Zaks said he moved to the United States because it offered him a greater chance to “fulfill my dream and translate science into medicine.”
“I hope that Israel will continue to develop its bio-tech sector. Wherever I can be most effective is where you’ll find me,” the 54-year-old scientist said.
The previous month, Zaks told the Post that his 80-year-old mother lives in Raanana, Israel, and that the virus derailed his plans to see her during Passover earlier this year.
“I want her to get vaccinated and the rest of us to get vaccinated so life can return to normal,” he said. “I take this responsibility deeply and personally.”
Moderna’s vaccine will likely not be ready for mass distribution until the spring, but reports claim that it can survive in less extreme temperatures than the one by Pfizer, which requires special refrigeration. The Pfizer vaccine claimed recently to be 90% effective.
Pfizer CEO Albert Bourla is from a Jewish family in Thessaloniki, Greece, and its head scientist, Mikael Dolsten, is from a Jewish family in Sweden.
Help ensure Jewish news remains accessible to all. Your donation to the Jewish Telegraphic Agency powers the trusted journalism that has connected Jewish communities worldwide for more than 100 years. With your help, JTA can continue to deliver vital news and insights. Donate today.
